Ionis Pharmaceuticals’ Donidalorsen Shows Promise in Treating Rare Swelling Disease, Hereditary Angioedema
Ionis Pharmaceuticals reported that its drug, Donidalorsen, significantly reduced attacks in patients with hereditary angioedema, a [...]
Lutathera’s Promise: A Potential $1 Billion First-Line Treatment Market
Novartis's drug Lutathera showed promise in a phase 3 trial for treating certain advanced gastroenteropancreatic neuroendocrine [...]
Revolutionizing IVF: UC San Diego Researchers Develop Non-Invasive Embryo Quality Prediction Method
Researchers at UC San Diego School of Medicine have developed a new method to improve the [...]
Revolutionizing Cancer Care: Integration of Genomic and Clinical Data in Precision Oncology
This study, published in Nature Medicine and led by institutions like Genomics England, NHS England, and [...]
Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults
Watch this webinar on addressing early onset cancer through strategic trial design, targeted launch indications, and increased trial access to speed up the delivery of impactful treatments.
Shifting the Paradigm to Pragmatic Evidence Generation
By: Richard Gliklich, MD, OM1 & Sonja Wustrack, MPH, OM1 Integrated Evidence Generation Integrated evidence generation (IEG) is a framework [...]
FTC Challenges Sanofi’s Deal for Pompe Disease Treatment, Citing Monopoly Concerns
The Federal Trade Commission (FTC) is challenging Sanofi’s proposed $755 million deal to license Maze Therapeutics’ [...]
FDA Gives First Approval for Novartis’ Iptacopan, a Revolutionary Oral Treatment for Rare Blood Disorder PNH
Novartis has received FDA approval for iptacopan, an innovative oral treatment for paroxysmal nocturnal hemoglobinuria (PNH), [...]
Balancing Public Health and Environmental Sustainability: Insights from the Unitaid Report
The recent Unitaid report highlights a complex issue in climate change: the significant environmental impact of [...]
Merck’s Pneumococcal Vaccine V116 Matches Pfizer’s Prevnar 20 in Phase 3 Trial
Merck’s investigational pneumococcal vaccine V116 demonstrated efficacy and safety levels similar to Pfizer’s Prevnar 20 vaccine [...]
Bayer’s Asundexian Fails in Phase 3 Trial, Impacting 5 Billion Euro Annual Revenue Plan
Bayer's plans to make Asundexian into a 5 billion euro per year product have faced a [...]
NIH’s New Director Monica Bertagnolli Concerned about Obesity; Emphasizes the Importance of Clinical Trials and Role of Insurers in Healthcare Research
Newly appointed NIH director Monica Bertagnolli expressed her concern about obesity and highlighted the importance of [...]
FDA Approves Takeda’s Novel, Chemotherapy-Free Pill Fruzaqla for Metastatic Colorectal Cancer
The FDA approved Takeda’s Fruzaqla, a pill treatment for refractory metastatic colorectal cancer (mCRC), making it [...]
Izervay’s Efficacy Increases Over Time, Outpacing Competitor in Treating Geographic Atrophy: 2-Year GATHER2 Study Finds
Astellas' drug Izervay, a treatment for eye condition geographic atrophy, has demonstrated an increase in efficacy [...]
ASN Kidney Week 2023: Studies Highlight Issues in CKD Diagnosis Delays and Management Using Real-World Data
Two posters presented at ASN Kidney Week 2023 analyzed real-world data on Chronic Kidney Disease (CKD) [...]
FDA Approves Novartis’ Cosentyx as First New Biologic HS Treatment in Decade: A Potential Rival for AbbVie’s Humira
The U.S. FDA has approved Novartis' Cosentyx (secukinumab) for treating moderate to severe hidradenitis suppurativa (HS), [...]
Olympus Asks Healthcare Providers to Stop Using Its Insufflator Units Due to Over-Inflation Reports; FDA Issues Class I Recall
Olympus, a healthcare equipment company, has asked healthcare providers to stop using its UHI-4 insufflator unit, [...]
Confirmatory Study for Sarepta and Roche’s Duchenne Gene Therapy Fails to Hit Primary Endpoint
Sarepta and Roche's confirmatory Phase III EMBARK study for Duchenne muscular dystrophy gene therapy, Elevidys, failed [...]
The Future of Diversity in Clinical Trials: Real-World Evidence
This episode of tHEORetically Speaking features real-world evidence experts Alexandrina Balanean, Parisa Asgarisabet, and Danielle Gentile from Cardinal Health discussing the problems caused by lack of diverse representation in clinical trials.
The Future of Diversity in Clinical Trials: Real-World Evidence
This episode of tHEORetically Speaking features real-world evidence experts Alexandrina Balanean, Parisa Asgarisabet, and Danielle Gentile from Cardinal Health discussing the problems caused by lack of diverse representation in clinical trials.
Revolutionizing Antibiotics: Harnessing Molecular De-Extinction and AI in the Hunt for New Treatments from Extinct Animals’ DNA
Cesar de la Fuente and his lab at the University of Pennsylvania are utilizing algorithms in [...]
Prescription Drug Use Expected for Half of Americans’ Lifetimes, Study Finds
A recent study by Jessica Ho, associate professor at Penn State University, found that Americans born [...]
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
This webinar delves into the dynamic landscape of COAs, examining their historical use and significance, current uses and best practices, and making a case for greater standardization in their implementation.
Gero Secures $6M in Series A Extension Round to Advance AI-Based Age-Related Disease Research
Biotechnology company Gero has secured $6M in a Series A extension round led by Melnichek Investments. [...]
Key Steps to Enhance Success Rate and Validity in Pharmaceutical Clinical Trials
Bringing a new drug to market takes pharmaceutical companies 10 to 15 years and more than [...]
